Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform^™ drug optimization technology, today announced the closing of a $5 million financing from strategic shareholders. Proceeds from the transaction will support the continued development of SER-252 (POZ-apomorphine), Serina's lead clinical candidate for Advanced Parkinson's disease, as the company prepares to initiate a Phase 1 clinical trial in the fourth quarter of 2025.

“This financing further strengthens our cash position and reflects the confidence of our strategic investors in the potential of SER-252,” said Steve Ledger, CEO of Serina Therapeutics. “With a novel approach to achieving continuous dopaminergic stimulation, we believe SER-252 may offer meaningful clinical benefit to patients with advanced Parkinson’s disease. We remain focused on initiating first-in-human studies later this year.”

In connection with the financing, Serina issued 965,250 shares of convertible preferred stock at $5.18 per share, equivalent to the closing price of its common stock on April 7, 2025.